Nov 3 (Reuters) – * SAFI BIOTHERAPEUTICS AWARDED A $4.7 MILLION EXTENSION BY U.S. DOW TO ADVANCE MANUFACTURED RED BLOOD CELLS TOWARD FIRST CLINICAL TRIAL * SAFI BIOTHERAPEUTICS: PLANS IND SUBMISSION
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oil prices slide about 2% to multi-week low amid peace talks
By Scott DiSavino NEW YORK, Nov 3 (Reuters) - Oil prices slid about 2% to…
German climber to make rare winter attempt to scale Everest via West Ridge route
VIDEO SHOWS: INTERVIEW WITH GERMAN ALPINIST, JOST KOBUSCH, WHO IS ATTEMPTING TO CLIMB MOUNT EVEREST…
BRIEF-Zew Kogeneracja Prelim. Q3 Electricity Production At 566 Gwh
Nov 3 (Reuters) - Zespol Elektrocieplowni Wroclawskich Kogeneracja SA: * PRELIM. Q3 2026 ELECTRICITY PRODUCTION…
